Point72 Asset Management
VVOS icon

Point72 Asset Management’s Vivos Therapeutics VVOS Stock Holding History

Point72 Asset Management’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,811
Closed -$456K – 1658
2022
Q1 		$456K Buy
+6,811
New +$445K ﹤0.01% 1025

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's VVOS Position: Q2 2022 in Review

Point72 Asset Management sold out of Vivos Therapeutics (VVOS) in Q2 2022, closing a stake of 6,811 shares — an estimated $456K sold.

Point72 Asset Management first reported a position in VVOS in Q1 2022 and held it in 1 quarter. The position peaked at $456K in Q1 2022. 27 funds tracked by Wall St. Rank hold VVOS as of Q2 2022.

  • Point72 Asset Management reported no remaining Vivos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Point72 Asset Management sold 6,811 Vivos Therapeutics shares in Q2 2022, an estimated $456K.
  • Point72 Asset Management first reported a position in Vivos Therapeutics in Q1 2022 and held it in 1 quarter.
  • Point72 Asset Management's Vivos Therapeutics position peaked at $456K in Q1 2022.
  • 27 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2022.

Based on Point72 Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.